TABLE 5.
Prevalence of molecular markers of resistance among samples from malaria cases
| Genotype | % (no./total) in group |
Odds ratio (95% CI) [P] |
||||
|---|---|---|---|---|---|---|
| DHAPQ | SPAQ | No SMC | SPAQ vs. DHAPQ | DHAPQ vs. no SMC | SPAQ vs. no SMC | |
| pfcrt CVIET T76 | 62.9 (66/105) | 61 (50/82) | 61.5 (24/39) | 0.9 (0.5 to 1.7) [0.79] | 1.1 (0.5 to 2.4) [0.88] | 0.98 (0.4 to 2.3) [0.97] |
| pfmdr1 Y86 | 33 (30/91) | 44.4 (28/63) | 30.4 (24/79) | 1.6 (0.8–3.3) [0.14] | 0.7 (0.3–1.5) [0.33] | 1.8 (0.9–3.9) [0.08] |
| pfmdr1 Y184 | 36.4 (32/88) | 32.3 (20/62) | 39.2 (31/79) | 1.2 (0.6–2.5) [0.6] | 0.9 (0.5–1.7) [0.7] | 0.7 (0.3–1.6) [0.3] |
| pfdhfr i51 | 40.6 (54/133) | 64 (64/100) | 51.3 (41/80) | 2.6 (1.5–4.6) [<0.001] | 0.7 (0.4–1.2) [0.1] | 1.6 (0.9–3.2) [0.08] |
| pfdhfr s108 | 58.3 (77/132) | 27 (27/100) | 70 (56/80) | 0.3 (0.1–1.5) [<0.001] | 0.6 (0.3–1.1) [0.08] | 0.2 (0.1–0.3) [<0.001] |
| pfdhfr r59 | 43.6 (58/133) | 71 (71/100) | 53.75 (43/80) | 3.2 (1.8–5.7) [<0.001] | 0.7 (0.4–1.2) [0.15] | 2.1 (1.1–4.1) [0.01] |
| pfdhps g437 | 63.4 (85/134) | 84 (84/100) | 75 (48/64) | 3 (1.5–6.1) [<0.001] | 0.6 (0.3–1.2) [0.10] | 1.8 (0.7–4.1) [0.15] |
| pfdhps s613 | 6.5 (19/138) | 6.9 (7/101) | 13.6 (9/66) | 1.1 (0.3–3.3) [0.9] | 0.4 (0.1–1.3) [0.09] | 0.5 (0.4–1.5) [0.1] |
| pfmdr1 Y86 + pfcrt T76 (CVIET) | 3.3 (5/149) | 6 (7/116) | 1.2 (1/81) | 1.8 (0.5–7.6) [0.29] | 2.8 (0.3–133) [0.33] | 5.3 (0.6–234) [0.09] |
| pfmdr1 Y184 + pfcrt T76 (CVIET) | 3.3 (5/149) | 3.4 (4/116) | 6.2 (5/81) | 1 (0.2–4.9) [0.96] | 0.5 (0.1–2.4) [0.31] | 0.5 (0.1–2.6) [0.36] |
| pfdhfr I51/R59/S108 | 30.9 (38/123) | 53.2 (50/94) | 33.9 (20/59) | 2.5 (1.4–4.6) [0.001] | 1.1 (0.6–2.4) [0.68] | 2.1 (1.1–4.6) [0.01] |
| pfdhfr I51/R59/S108 + pfdhps G437 | 19.5 (24/123) | 41.5 (39/94) | 23.7 (14/59) | 2.9 (1.5–5.6) [<0.001] | 0.8 (0.3–1.8) [0.5] | 2.3 (1.1–5.1) [0.02] |